SCI Pharmtech, Inc. (4119.TW)
TWD 69.9
(-0.57%)
TWD 69.9
(-0.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 529.61 Million TWD | 4.71% |
| 2022 | 492.06 Million TWD | 289.65% |
| 2021 | 142.8 Million TWD | -78.94% |
| 2020 | 603.01 Million TWD | -28.38% |
| 2019 | 847.94 Million TWD | 24.4% |
| 2018 | 647.96 Million TWD | 88.66% |
| 2017 | 361.34 Million TWD | -43.95% |
| 2016 | 639.94 Million TWD | 8.28% |
| 2015 | 569.84 Million TWD | 23.61% |
| 2014 | 430.06 Million TWD | 49.62% |
| 2013 | 328.84 Million TWD | -8.8% |
| 2012 | 357.88 Million TWD | 14.7% |
| 2011 | 305.51 Million TWD | -0.54% |
| 2010 | 307.3 Million TWD | 0.25% |
| 2009 | 307.31 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 114.95 Million TWD | 2.09% |
| 2024 Q1 | 109.3 Million TWD | 171.71% |
| 2023 Q3 | 80.13 Million TWD | -72.39% |
| 2023 Q4 | 37.9 Million TWD | -52.7% |
| 2023 Q1 | 109.98 Million TWD | -14.92% |
| 2023 Q2 | 290.2 Million TWD | 163.86% |
| 2023 FY | - TWD | 4.71% |
| 2022 Q2 | 200.54 Million TWD | 179.58% |
| 2022 FY | - TWD | 289.65% |
| 2022 Q1 | 71.73 Million TWD | 589.07% |
| 2022 Q4 | 129.27 Million TWD | 38.46% |
| 2022 Q3 | 93.36 Million TWD | -53.45% |
| 2021 Q1 | 65.54 Million TWD | 120.94% |
| 2021 Q3 | 56.54 Million TWD | 188.68% |
| 2021 Q2 | 19.58 Million TWD | -70.12% |
| 2021 FY | - TWD | -78.94% |
| 2021 Q4 | -14.66 Million TWD | -125.94% |
| 2020 FY | - TWD | -28.38% |
| 2020 Q2 | 318.16 Million TWD | -1.18% |
| 2020 Q3 | 275.96 Million TWD | -13.26% |
| 2020 Q4 | -313.08 Million TWD | -213.45% |
| 2020 Q1 | 321.97 Million TWD | 129.28% |
| 2019 Q1 | 232.96 Million TWD | 39.46% |
| 2019 Q4 | 140.43 Million TWD | -39.67% |
| 2019 FY | - TWD | 24.4% |
| 2019 Q3 | 232.76 Million TWD | -1.27% |
| 2019 Q2 | 235.76 Million TWD | 1.2% |
| 2018 Q3 | 189.55 Million TWD | -12.34% |
| 2018 FY | - TWD | 88.66% |
| 2018 Q4 | 167.05 Million TWD | -11.87% |
| 2018 Q2 | 216.24 Million TWD | 94.83% |
| 2018 Q1 | 110.98 Million TWD | 9.75% |
| 2017 Q4 | 101.13 Million TWD | 26.17% |
| 2017 FY | - TWD | -43.95% |
| 2017 Q1 | 95.87 Million TWD | 29.99% |
| 2017 Q2 | 84.4 Million TWD | -11.97% |
| 2017 Q3 | 80.15 Million TWD | -5.04% |
| 2016 Q1 | 223 Million TWD | 108.01% |
| 2016 Q3 | 146.64 Million TWD | -25.42% |
| 2016 Q4 | 73.75 Million TWD | -49.7% |
| 2016 FY | - TWD | 8.28% |
| 2016 Q2 | 196.63 Million TWD | -11.83% |
| 2015 Q1 | 150.49 Million TWD | 44.27% |
| 2015 Q2 | 184.89 Million TWD | 22.86% |
| 2015 FY | - TWD | 23.61% |
| 2015 Q3 | 148.5 Million TWD | -19.68% |
| 2015 Q4 | 107.2 Million TWD | -27.81% |
| 2014 Q2 | 148.8 Million TWD | 28.29% |
| 2014 Q4 | 104.31 Million TWD | -4.36% |
| 2014 FY | - TWD | 49.62% |
| 2014 Q1 | 115.99 Million TWD | 44.49% |
| 2014 Q3 | 109.07 Million TWD | -26.7% |
| 2013 FY | - TWD | -8.8% |
| 2013 Q3 | 61.11 Million TWD | -28.26% |
| 2013 Q4 | 80.27 Million TWD | 31.36% |
| 2013 Q2 | 85.18 Million TWD | -9.35% |
| 2013 Q1 | 93.96 Million TWD | -0.81% |
| 2012 Q2 | 71.98 Million TWD | -24.1% |
| 2012 Q1 | 94.83 Million TWD | 22.85% |
| 2012 Q4 | 94.73 Million TWD | 6.03% |
| 2012 Q3 | 89.35 Million TWD | 24.13% |
| 2012 FY | - TWD | 14.7% |
| 2011 Q3 | 75.99 Million TWD | 10.83% |
| 2011 Q1 | 83.76 Million TWD | 3.54% |
| 2011 Q2 | 68.56 Million TWD | -18.14% |
| 2011 FY | - TWD | -0.54% |
| 2011 Q4 | 77.19 Million TWD | 1.59% |
| 2010 FY | - TWD | 0.25% |
| 2010 Q2 | 82.67 Million TWD | 14.62% |
| 2010 Q1 | 72.12 Million TWD | 0.0% |
| 2010 Q4 | 80.89 Million TWD | 13.2% |
| 2010 Q3 | 71.46 Million TWD | -13.56% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Grape King Bio Ltd | 2.88 Billion TWD | 81.642% |
| Standard Chem & Pharm CO., LTD. | 1.57 Billion TWD | 66.458% |
| Maywufa Company Ltd. | 239.81 Million TWD | -120.843% |
| ScinoPharm Taiwan, Ltd. | 819.15 Million TWD | 35.346% |
| Lotus Pharmaceutical Co., Ltd. | 6.87 Billion TWD | 92.292% |
| LIWANLI Innovation Co., Ltd. | 6.81 Million TWD | -7676.99% |
| YungShin Global Holding Corporation | 1.35 Billion TWD | 60.982% |
| PhytoHealth Corporation | -20.69 Million TWD | 2658.764% |
| Formosa Laboratories, Inc. | 1.16 Billion TWD | 54.473% |
| PharmaEssentia Corporation | -671.48 Million TWD | 178.872% |
| Bora Pharmaceuticals Co., LTD. | 5.73 Billion TWD | 90.764% |